# Bolt Biotherapeutics to Participate in Upcoming September Conferences
Canonical URL: https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-september-conferences-ae911c1e
Ticker: BOLT
Company: Bolt Biotherapeutics
Source: Bolt Biotherapeutics
Published: 2024-08-28 11:00 EST
## Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...

## Article Body
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:

Morgan Stanley 22 nd Annual Global Healthcare Conference Fireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT)

H.C. Wainwright 26 th Annual Global Investment Conference Company presentation available on Monday, Sept. 9, at 7:00am EDT (4:00 a.m. PDT)

A webcast of the presentations will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/ .

Investor Relations and Media Contact: Matthew DeYoung Argot Partners (212) 600-1902 boltbio@argotpartners.com
## Recent Company News
- 2026-05-12 20:05 EST — [Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-b-b5fec9e5) — Source: Bolt Biotherapeutics
- 2026-03-12 20:05 EST — [Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-e284d9b8) — Source: Bolt Biotherapeutics
- 2026-02-24 13:00 EST — [Bolt Biotherapeutics to Participate in Upcoming March Conferences](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-d58ae5f3) — Source: Bolt Biotherapeutics
- 2025-11-12 21:05 EST — [Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-reports-third-quarter-2025-financial-results-and-provides-b-237a81ff) — Source: Bolt Biotherapeutics
- 2025-10-01 20:05 EST — [Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027](https://biopharmsignal.com/news/BOLT/bolt-biotherapeutics-provides-update-on-bdc-4182-and-extends-cash-runway-into-20-8bbaa910) — Source: Bolt Biotherapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)